Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SQZ-PBMC-HPV
- Development stage
- Phase 1
- Lead developer
- SQZ Biotechnologies
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
SQZ-PBMC-HPV is an investigational autologous cell therapy developed using the Cell Squeeze platform by SQZ Biotechnologies. It consists of peripheral blood mononuclear cells (PBMCs) collected from the patient and loaded with immunogenic epitopes of human papillomavirus (HPV) type 16 E6 and E7 oncoproteins. The process uses microfluidic squeezing technology to introduce these antigens into PBMCs, generating enhanced antigen presenting cells (eAPCs). These eAPCs are designed to stimulate a robust CD8+ T cell immune response against HPV16+ tumor cells, offering potential immunomodulating and antineoplastic activity. The therapy is being evaluated for advanced or metastatic solid tumors that are positive for HPV16, including cervical, head and neck, and anal cancers. Early clinical studies have shown favorable safety profiles and evidence of immune activation in patients previously refractory to checkpoint inhibitors[1][2][3][4][5][6][7].
- Other names
- antigen-presenting cells-expressing HPV16 E6/E7 SQZ-PBMC-HPV
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)HPV16 E6/E7 TCR (HPV16 E6/E7-specific T-cell receptor)
Beyond the preview
Go deeper on SQZ-PBMC-HPV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SQZ-PBMC-HPV.